Failure rates have decreased since the CXCR4 antagonist plerixafor was approved for the mobilization of HSPCs for MM and non-Hodgkin lymphoma patients when given in conjunction with G-CSF133–135. This evidence concerns the gene CXCR4 and non-Hodgkin lymphoma.